- Home
- ONEG vs IXHL Comparison
ONEG vs IXHL Comparison
Compare ONEG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ONEG | IXHL |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | Hong Kong | Australia |
| Employees | 26 | N/A |
| Industry | Homebuilding | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 37.0M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | ONEG | IXHL |
|---|---|---|
| Price | $1.16 | $3.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 253.2K | ★ 255.9K |
| Earning Date | 01-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.16 |
| 52 Week High | $14.95 | $6.39 |
Technical Indicators
Market Signals| Indicator | ONEG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 42.89 |
| Support Level | $1.13 | $2.68 |
| Resistance Level | $1.98 | $3.68 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 7.69 | 24.08 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.